Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas
- PMID: 9662595
- DOI: 10.1007/s002590050276
Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas
Abstract
The aim of this study was to investigate whether uptake of carbon-11 methionine (MET) is associated with histological grade of malignancy and survival in patients with newly diagnosed or recurrent lymphoma. Thirty-two patients with histologically confirmed lymphoma participated in the study. Twenty-six (81%) were studied before any therapy and six before treatment for recurrent disease. Twenty-eight patients had non-Hodgkin's lymphoma and four had Hodgkin's disease. An ECAT 931/08-12 positron emission tomography (PET) scanner was used for PET imaging. After the transmission scan, a median dose of 293 MBq of MET was injected intravenously and dynamic images were acquired for 40 min. The uptake of MET in tumour was measured as the standardized uptake value (SUV) and influx constant (Ki). The SUV formula was also adjusted to the predicted value of lean body mass (SUVlean) and body surface area (SUVBSA). The PET results were correlated with the clinical follow-up data. The median SUV in 32 malignant lesions was 6.6 (range, 1.9-12.4) and the median Ki was 0. 116 min-1 (range, 0.025-0.201, n=23). The median SUV was 7.0 (range, 5.4-12.4, n=9) in high, 6.2 (range, 1.9-10.4, n=11) in intermediate and 5.7 (range, 3.8-8.3, n=8) in low grade lymphomas. One intermediate grade lymphoma of the skin was visually negative (SUV 1. 9). In Hodgkin's disease the median SUV was 7.0 (range, 3.2-7.9, n=4). The median Ki value was 0.162 min-1 (range, 0.147-0.197, n=7) in high, 0.099 (range, 0.025-0.152, n=10) in intermediate, and 0.078 (range, 0.056-0.152, n=4) in low grade lymphomas and 0.149 (range, 0. 096-0.201, n=2) in Hodgkin's disease. The difference between high and other grade non-Hodgkin's lymphomas was significant when using Ki (P<0.001), but not with SUV, SUVlean or SUVBSA. The final outcome of the patients was not related to MET uptake. Lymphomas with a high Ki value tended to have a high S-phase fraction (r2=0.46, P=0.043). It is concluded that MET PET is highly sensitive for the detection of untreated and recurrent lymphomas. Differentation of high grade lymphomas from lower malignancy grades seems to be possible if graphical analysis is applied to calculate Ki for MET. However, prediction of survival is not possible with MET PET.
Similar articles
-
The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.Laryngoscope. 2010 May;120(5):937-44. doi: 10.1002/lary.20843. Laryngoscope. 2010. PMID: 20422687
-
Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.Nuklearmedizin. 2001 Feb;40(1):23-30. Nuklearmedizin. 2001. PMID: 11373935
-
Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography.Radiother Oncol. 1999 Sep;52(3):225-32. doi: 10.1016/s0167-8140(99)00091-2. Radiother Oncol. 1999. PMID: 10580868
-
Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.Clin Lymphoma. 2002 Jun;3(1):56-61. doi: 10.3816/clm.2002.n.012. Clin Lymphoma. 2002. PMID: 12141957 Review.
-
Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.Curr Probl Diagn Radiol. 2006 Jul-Aug;35(4):151-63. doi: 10.1067/j.cpradiol.2006.02.001. Curr Probl Diagn Radiol. 2006. PMID: 16814002 Review.
Cited by
-
(11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas.Tumour Biol. 2014 Dec;35(12):12353-60. doi: 10.1007/s13277-014-2549-x. Epub 2014 Sep 3. Tumour Biol. 2014. PMID: 25182853
-
Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study.Eur J Hybrid Imaging. 2020 Aug 26;4(1):15. doi: 10.1186/s41824-020-00083-x. Eur J Hybrid Imaging. 2020. PMID: 34191157 Free PMC article.
-
Current molecular imaging of spinal tumors in clinical practice.Mol Med. 2011 Mar-Apr;17(3-4):308-16. doi: 10.2119/molmed.2010.00218. Epub 2011 Jan 3. Mol Med. 2011. PMID: 21210073 Free PMC article. Review.
-
Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS.J Neurooncol. 2003 May;62(3):329-38. doi: 10.1023/a:1023342516925. J Neurooncol. 2003. PMID: 12777086
-
The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.Hematol Rep. 2024 Nov 27;16(4):752-768. doi: 10.3390/hematolrep16040072. Hematol Rep. 2024. PMID: 39728002 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous